Cannara Biotech First Quarter 2025 Earnings: EPS: CA$0.026 (vs CA$0.023 in 1Q 2024)

Cannara Biotech (CVE:LOVE) First Quarter 2025 Results

Key Financial Results

• Revenue: CA$25.1m (up 29% from 1Q 2024).
• Net income: CA$2.31m (up 9.4% from 1Q 2024).
• Profit margin: 9.2% (down from 11% in 1Q 2024).
• EPS: CA$0.026 (up from CA$0.023 in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cannara Biotech shares are up 13% from a week ago.

Risk Analysis

Be aware that Cannara Biotech is showing 5 warning signs in our investment analysis and 1 of those doesn't sit too well with us...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.